Abiopharma

STOKE THERAPEUTICS, INC. (STOK)

Symbol	STOK
Name	STOKE THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	45 WIGGINS AVENUE, BEDFORD, Massachusetts, 01730, United States
Telephone	+1 781 430-8200
Fax	—
Email	—
Website	https://www.stoketherapeutics.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001623526
Description	Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Additional info from NASDAQ: Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

2026-09-02 12:00

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

2026-09-01 11:30

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

2026-08-19 00:29

Ticho Barry 🟡 adjusted position in 4.8K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $32.47 Transaction Date: Aug 14, 2026 | Filing ID: 000019

2026-08-19 00:28

Kaye Edward M. MD 🟡 adjusted position in 12.6K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $32.47 Transaction Date: Aug 14, 2026 | Filing ID: 000007

2026-08-19 00:27

Allan Jonathan 🟡 adjusted position in 2.9K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $32.47 Transaction Date: Aug 14, 2026 | Filing ID: 000012

2026-08-18 20:01

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

2026-08-14 17:38

New Form SCHEDULE 13G/A - Stoke Therapeutics, Inc. Filed: 2026-08-14 AccNo: 0000902664-26-003525 Size: 10 KB

2026-08-12 17:10

New Form SCHEDULE 13G/A - Stoke Therapeutics, Inc. Filed: 2026-08-12 AccNo: 0000947263-26-000071 Size: 11 KB

2026-08-05 12:00

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

2026-08-03 21:06

(99% Neutral) STOKE THERAPEUTICS, INC. (STOK) Announces Business Combination

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT06872125	A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorev…	Phase3	Dravet Syndrome	Recruiting	2025-06-04	2028-10-01	ClinicalTrials.gov
NCT04740476	An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome	Phase2	Dravet Syndrome	Active_Not_Recruiting	2021-01-20	2029-03-31	ClinicalTrials.gov
NCT04442295	An Open-Label Study to Investigate the Safety of Single and Multiple Ascending …	Phase1	Dravet Syndrome	Completed	2020-06-29	2023-11-14	ClinicalTrials.gov

Total clinical trials: 3

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
STK-001 - Multiple Ascending Doses	Other	Phase PHASE1	Dravet Syndrome	COMPLETED	NCT04442295
STK-001 - Single Ascending Doses	Other	Phase PHASE1	Dravet Syndrome	COMPLETED	NCT04442295
zorevunersen (STK-001)	Other	Phase PHASE2	Dravet Syndrome	ACTIVE_NOT_RECRUITING	NCT04740476
Sham Comparator	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	Other	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
Sham Comparator	OTHER	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen	DRUG	Phase PHASE3	Dravet Syndrome	RECRUITING	NCT06872125
zorevunersen (STK-001)	DRUG	Phase PHASE2	Dravet Syndrome	ACTIVE_NOT_RECRUITING	NCT04740476
STK-001 - Multiple Ascending Doses	DRUG	Phase PHASE1	Dravet Syndrome	COMPLETED	NCT04442295
STK-001 - Single Ascending Doses	DRUG	Phase PHASE1	Dravet Syndrome	COMPLETED	NCT04442295

Total products: 30